Ceftazidime-Avibactam + Aztreonam for Pseudomonas and Klebsiella UTI
Yes, ceftazidime-avibactam (Zavicefta) combined with aztreonam can effectively cover both Pseudomonas aeruginosa and Klebsiella species in urinary tract infections, but the combination is specifically indicated for metallo-β-lactamase (MBL)-producing strains, not routine infections.
When This Combination is Appropriate
For Klebsiella Species (Excellent Coverage)
- Ceftazidime-avibactam alone is highly effective for most carbapenem-resistant Klebsiella pneumoniae (CRKP), particularly KPC-producing and OXA-48-producing strains, with nearly 100% susceptibility 1
- Add aztreonam only when MBL-production is confirmed or strongly suspected (NDM-producing strains), where the combination shows 96-97% synergism in urine isolates 2, 3
- For non-MBL-producing Klebsiella UTIs, ceftazidime-avibactam monotherapy is sufficient and preferred 4
For Pseudomonas aeruginosa (Limited Coverage)
- This combination has significantly lower activity against Pseudomonas compared to Klebsiella
- Synergism in urine isolates is only 17.6% for P. aeruginosa versus 96% for Klebsiella 2
- For carbapenem-resistant P. aeruginosa (CRPA), ceftolozane-tazobactam is the preferred first-line agent if active in vitro 4
- Ceftazidime-avibactam shows 95.7% susceptibility against P. aeruginosa overall, but aztreonam adds minimal benefit (only 78.6% susceptible at ≤8 mg/L) 5
Critical Decision Algorithm
Step 1: Identify the carbapenemase type
- KPC or OXA-48 producers → Use ceftazidime-avibactam alone 1
- MBL producers (NDM, VIM, IMP) → Use ceftazidime-avibactam plus aztreonam 1
- Unknown carbapenemase → Consider empiric combination for severe infections pending molecular testing 1
Step 2: Consider organism-specific factors
- Klebsiella/E. coli with MBL → Combination shows 95-98% synergy 2, 6, 3
- Pseudomonas with MBL → Combination shows only 33-37% synergy; consider alternative agents 2
Step 3: Assess infection severity
- Non-severe UTI with susceptible organism → Monotherapy acceptable 4
- Severe infection or bloodstream involvement → Combination therapy reduces 30-day mortality from 44% to 19.2% (HR 0.37) 1
Important Caveats
FDA-Approved Indications
Aztreonam is FDA-approved for complicated and uncomplicated UTIs caused by E. coli, K. pneumoniae, P. mirabilis, and P. aeruginosa 7. However, this approval predates the emergence of MBL-producing strains and combination therapy data.
Synergy Testing Considerations
- Not all isolates show synergy - laboratory confirmation is recommended when feasible 2, 6
- Disc elution and E-strip methods show 96.4% concordance for synergy testing 6
- Inappropriate use without synergy confirmation wastes resources and promotes resistance 2
Quality of Evidence Limitations
The recommendation for ceftazidime-avibactam plus aztreonam carries only weak recommendation strength with very low-quality evidence 1. Most data comes from observational studies of bloodstream and intra-abdominal infections, with limited specific UTI data.
Practical Recommendations
For empiric therapy of suspected MBL-producing organisms in urine:
- Use the combination if patient has risk factors (prior carbapenem exposure, healthcare-associated infection, known local MBL prevalence)
- De-escalate to monotherapy once susceptibilities confirm non-MBL mechanism 4
For targeted therapy:
- Klebsiella with confirmed MBL → Combination therapy
- Pseudomonas with confirmed MBL → Consider ceftolozane-tazobactam or cefiderocol as alternatives given poor synergy rates 4, 8
- Pan-drug resistant isolates → Combination shows synergy in 100% of cases 3
The combination provides excellent coverage for MBL-producing Klebsiella in urine but offers limited advantage for Pseudomonas aeruginosa, where alternative agents should be strongly considered.